GBA1 gene therapy (UCB Biopharma/KU Leuven/Center for applied medical research University of Navarra/Centro de Investigacion en Red de Enfermedades Neurodegenerativas)

N/A

Report date: 2025/06/11 10:53:32

Base Information

Drug NameGBA1 gene therapy (UCB Biopharma/KU Leuven/Center for applied medical research University of Navarra/Centro de Investigacion en Red de Enfermedades Neurodegenerativas)
Drug Alias NameAAV-TT-hGBA1
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionBeta-glucocerebrosidase stimulants
TargetsBeta-glucocerebrosidase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKu Leuven
China Registration ClassN/A

Develop Information

Active CompaniesCentro De Investigacion Biomedica En Red De Enfermedades NeurodegenerativasCenter for Applied Medical ResearchUcb Biopharma Sprl +[4] 
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A